Survodutide Research Guide — Dual GLP-1R/GCGR Agonist, Glucagon Axis Energy Expenditure & Phase 2/3 Clinical Data (2026)
- Survodutide (development code BI 456906; also designated ZP2929 in some trial documentation) is a 29-amino acid synthetic dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), developed by Boehringer Ingelheim. It is derived from the glucagon peptide backbone with strategic amino acid substitutions that introduce GLP-1R activity while retaining GCGR agonism, plus a C18 fatty diacid modification at the Lys-24 side chain (via a linker) that extends plasma half-life to support once-weekly subcutaneous administration. Research-grade survodutide is available through the YPB catalog (Research Use Only).
- Dual mechanism: GCGR agonism increases energy expenditure (hepatic glycogenolysis and gluconeogenesis; thermogenesis via brown adipose tissue activation; lipolysis in adipose tissue) while GLP-1R agonism reduces energy intake (hypothalamic appetite suppression; delayed gastric emptying; glucose-dependent insulin secretion). These are complementary, non-conflicting mechanisms — energy output up, energy input down — which is the pharmacological rationale for why dual agonism produces additive weight reduction vs. GLP-1R monotherapy alone.
- Phase 2 obesity data (*Lancet Diabetes Endocrinol* 2024, PMID: 38330987): Dose-dependent body weight reduction up to ~15%+ at survodutide 4.8 mg once-weekly vs. placebo at 46 weeks. Over 50% of participants receiving the highest dose achieved ≥15% weight reduction. GI adverse events (nausea, vomiting, diarrhea) most common; consistent with GLP-1R/GCGR class.
- Phase 2 MASH/fibrosis data (*NEJM* 2024, Sanyal et al., PMID: 38857022): Survodutide was superior to placebo for MASH improvement without worsening of fibrosis, with 64.5% fibrosis reduction in F2–F3 fibrosis subgroup. The GCGR component drives hepatic lipid oxidation and steatosis reduction, adding a direct liver benefit beyond the weight loss effect.
- Phase 3 SYNCHRONIZE program: Multiple Phase 3 trials ongoing as of April 2026. Not research-grade. Not equivalent to semaglutide or tirzepatide. YPB survodutide is Research Use Only. Updated April 2026.
What Is Survodutide and How Does Its Dual Receptor Mechanism Work?
Phase 3 SYNCHRONIZE Active
Energy Out + Appetite In: Dual Mechanism
Survodutide (BI 456906) is a 29-amino acid synthetic peptide dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed by Boehringer Ingelheim. Updated April 2026. The compound was engineered from the glucagon peptide backbone: glucagon is a 29-AA hormone secreted by pancreatic α-cells that shares structural homology with GLP-1 (both are members of the glucagon/secretin peptide superfamily and share the same class B GPCR receptor family). Rather than designing a de novo dual agonist peptide, survodutide was created by strategically modifying the native glucagon sequence to introduce GLP-1R agonist activity while retaining GCGR agonism, then adding a fatty diacid (C18) at Lys-24 via a linker to extend half-life to approximately 7 days for once-weekly subcutaneous dosing.
The key research distinction from semaglutide (GLP-1R monoagonist) and tirzepatide (GLP-1R/GIPR dual agonist) is the glucagon receptor component. Glucagon itself has historically been viewed primarily as a hyperglycemic counter-regulatory hormone, but its receptor (GCGR) has multiple metabolic effects beyond hepatic glucose output that make it attractive for obesity pharmacology: GCGR activation drives energy expenditure through thermogenesis, lipolysis, and enhanced hepatic fatty acid oxidation. Survodutide combines the GLP-1R appetite-suppressive, glucose-lowering, and gastric-emptying mechanisms with GCGR energy-expenditure-increasing mechanisms — addressing both sides of the energy balance equation simultaneously.
Key Characteristics
| Parameter | Value |
|---|---|
| Development Code | BI 456906 (Boehringer Ingelheim; also designated ZP2929 in some trial documentation) |
| Developer | Boehringer Ingelheim (in collaboration with Zealand Pharma) |
| Peptide Length | 29 amino acids; glucagon backbone with strategic substitutions for GLP-1R activity; C18 fatty diacid at Lys-24 side chain via linker |
| Primary Receptors | GCGR (glucagon receptor) and GLP-1R (glucagon-like peptide-1 receptor); both class B GPCRs; both Gs-coupled → cAMP signaling |
| GLP-1R vs. GCGR Selectivity | Approximately 8-fold selectivity for GLP-1R over GCGR (designed to ensure GLP-1R-mediated insulin secretion and appetite suppression predominate over glucagon’s hyperglycemic effects) |
| Half-Life | ~7 days (once-weekly SC dosing); extended by C18 fatty diacid albumin binding (same lipidation strategy as semaglutide) |
| Downstream Signaling | Both receptors: Gs → adenylyl cyclase → cAMP ↑ → PKA activation. GLP-1R: appetite suppression, GI motility reduction, glucose-dependent insulin secretion. GCGR: energy expenditure ↑ (thermogenesis, lipolysis, hepatic fatty acid oxidation, glycogenolysis) |
| vs. Semaglutide | Adds GCGR energy-expenditure component to GLP-1R appetite suppression; distinct from semaglutide (GLP-1R only) by the glucagon receptor axis |
| vs. Tirzepatide | Tirzepatide is GLP-1R + GIPR (GIP receptor); survodutide is GLP-1R + GCGR. Different second receptor; different downstream metabolic profiles |
| vs. Cagrilintide | Cagrilintide is AMY1R/AMY3R (amylin receptor; brainstem satiety); survodutide is GLP-1R + GCGR. Non-overlapping receptor systems |
| FDA Status | Not research-grade as of April 2026. Phase 3 SYNCHRONIZE program ongoing. Research Use Only (RUO). |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days. Lipidated peptide: use low-protein-binding containers at low concentrations to minimize adsorption |
The Dual Mechanism: Why GLP-1R + GCGR Produces Additive Metabolic Effects
The physiological rationale for the GLP-1R/GCGR dual agonism in survodutide is built on two receptor systems with distinct but complementary metabolic functions that together address the two primary sides of energy imbalance in obesity.
GLP-1R Component: Energy Intake Reduction
GLP-1R agonism (shared with semaglutide, liraglutide, and the GLP-1R component of tirzepatide) reduces energy intake through three established mechanisms: (1) hypothalamic appetite suppression via arcuate and paraventricular nucleus GLP-1R activation, reducing NPY/AgRP-mediated hunger drive; (2) gastric emptying inhibition via vagal NTS GLP-1R, extending nutrient-stimulated satiety and reducing meal portion size; and (3) glucose-dependent insulin secretion from pancreatic β-cells, improving postprandial glycemic control while reducing glucagon from α-cells. The GLP-1R component of survodutide provides the appetite and glycemic control foundation.
GCGR Component: Energy Expenditure Increase
The GCGR agonism is the mechanistically differentiating feature vs. GLP-1R monotherapy. Glucagon receptor activation drives energy expenditure through multiple pathways: (1) hepatic glycogenolysis and gluconeogenesis (directly countered by the concurrent GLP-1R-mediated insulin secretion, maintaining glucose homeostasis); (2) activation of brown adipose tissue (BAT) thermogenesis, increasing basal metabolic rate; (3) stimulation of adipose tissue lipolysis, increasing circulating free fatty acids as fuel; (4) increased hepatic fatty acid β-oxidation, reducing hepatic lipid accumulation (steatosis). This last effect is particularly relevant to survodutide’s documented MASH efficacy — the GCGR component directly addresses the hepatic steatosis that underlies metabolic-associated steatohepatitis.
The Apparent GLP-1/Glucagon Paradox and How Survodutide Resolves It
At first consideration, combining GLP-1R agonism (which suppresses glucagon from α-cells) with direct GCGR agonism (which stimulates glucagon receptor signaling) seems contradictory. The pharmacological design resolves this: survodutide provides exogenous GCGR activation at doses that overcome the GLP-1-mediated suppression of endogenous glucagon secretion, while the GLP-1R-mediated glucose-dependent insulin secretion ensures glycemic homeostasis despite the hepatic glucose output promoted by GCGR. In published Phase 2 data, survodutide did not produce significant hypoglycemia despite the GCGR component, consistent with the glucose-dependent (not glucose-independent) nature of GLP-1R-stimulated insulin secretion providing an automatic metabolic safety valve.
What Does the Phase 2 Clinical Data Show?
| Trial | Design / N | Key Finding & Adverse Events | Year |
|---|---|---|---|
| Phase 2 Obesity — Lancet Diabetes Endocrinol | Randomized, double-blind, placebo-controlled, dose-finding / adults with BMI ≥27 kg/m² without diabetes | Survodutide produced dose-dependent body weight reduction vs. placebo at 46 weeks; highest dose (4.8 mg once-weekly): ~15%+ mean weight reduction; >50% of participants achieved ≥15% weight loss. All tested doses were tolerated. Adverse events: GI (nausea, vomiting, diarrhea) most common; consistent with GCGR/GLP-1R class; predominantly during titration. (Lancet Diabetes Endocrinol, 2024 — PMID: 38330987) | 2024 |
| Phase 2 MASH/Fibrosis — NEJM | Randomized, double-blind, placebo-controlled / adults with biopsy-confirmed MASH and liver fibrosis (F1–F3) | Survodutide superior to placebo for MASH improvement without worsening of fibrosis. In F2–F3 fibrosis subgroup: 64.5% fibrosis reduction (vs. placebo). GCGR-mediated hepatic fatty acid oxidation and steatosis reduction proposed as primary mechanism for liver-specific effects beyond weight loss alone. Well tolerated; GI adverse events consistent with class. (Sanyal et al., NEJM, 2024 — PMID: 38857022) | 2024 |
| Phase 3 SYNCHRONIZE Program | Multiple Phase 3 trials; SYNCHRONIZE-1 (obesity without T2D), SYNCHRONIZE-2 (obesity with T2D), and others | Actively enrolling as of April 2026. Primary endpoints: body weight reduction vs. placebo; secondary: cardiovascular outcomes, glycemic markers, liver histology. Results pending. Not research-grade; NDA not yet filed as of April 2026. | Ongoing 2025–2026 |
How Does Survodutide Compare to Other Metabolic Research Compounds?
| Parameter | Survodutide | Cagrilintide | AOD 9604 | MOTS-c |
|---|---|---|---|---|
| Receptor System | GLP-1R + GCGR (dual; both class B Gs-coupled GPCRs) | AMY1R + AMY3R (amylin/calcitonin receptors; Gq/11-coupled; brainstem) | Proposed β3-adrenergic receptor; peripheral adipose lipolysis | No classical receptor; AMPK/AICAR pathway; mitochondrial |
| Energy Balance | Dual: GCGR ↑ energy expenditure + GLP-1R ↓ energy intake | Primarily appetite/satiety (GLP-1R complementary; hedonic hunger) | Peripheral lipolytic; fat mobilization | Mitochondrial energy metabolism; AMPK activation |
| Liver/MASH Data | Yes — Phase 2 NEJM 2024: 64.5% fibrosis reduction (F2–F3); direct GCGR-mediated hepatic fatty acid oxidation | No direct published MASH data | FDA Phase 2 (2000–2001) no significant liver focus | No published MASH data |
| Phase 3 Status | SYNCHRONIZE program active (multiple trials) | REDEFINE program; CagriSema NDA filed Dec 2025 | Phase 2 only; no Phase 3 | Phase 2 completed; no Phase 3 |
| GCGR Component | Yes — differentiating feature vs. GLP-1R monotherapy; energy expenditure driver + hepatic steatosis reduction | No GCGR activity | No GCGR activity | No GCGR activity |
| vs. Tirzepatide | Second receptor = GCGR (energy expenditure); tirzepatide’s second receptor = GIPR (incretin enhancement). Different pharmacological strategy for augmenting GLP-1R. | N/A | N/A | N/A |
| YPB position | YPB catalog — research-grade RUO | YPB.241 — see guide | YPB.248 — see guide | YPB.227 — see guide |
Survodutide and cagrilintide are often discussed together as the leading non-GLP-1R-monoagonist metabolic compounds in clinical development, but they target entirely different receptor systems. Cagrilintide (see the Cagrilintide Research Guide) activates AMY1R/AMY3R amylin receptors at the brainstem area postrema; survodutide activates GLP-1R and GCGR (class B GPCRs) at the gut, brain, liver, and adipose tissue. The two compounds are mechanistically non-overlapping tools for studying different aspects of obesity pharmacology research. The AOD 9604 Research Guide and MOTS-c Research Guide cover peripheral lipolytic and mitochondrial metabolic mechanisms respectively.
What Should Researchers Know About Survodutide Stability and Handling?
Lipidated Peptide Considerations
Like semaglutide and cagrilintide, survodutide incorporates a fatty diacid moiety (C18 at Lys-24 via a linker) that enables albumin binding for extended half-life. The lipid chain can cause adsorption to polypropylene surfaces at low nanomolar research concentrations; use low-protein-binding containers for dilute working solutions. The C18 fatty diacid also reduces aqueous solubility compared to unlipidated peptides; neutral-to-slightly-alkaline pH buffers (pH 7.0–7.4) in saline or PBS are appropriate for reconstitution.
Storage
Lyophilized survodutide is stable at −20°C for up to 24 months. Reconstituted: 2–8°C, use within 14 days. Avoid repeated freeze-thaw cycles. All YPB survodutide batches include lot-traceable COA documentation through the COA Library.
COA Verification
HPLC purity (≥98%) and MS confirmation at the correct MW for the 29-AA lipidated form. The C18 fatty diacid addition produces a substantial MW increase vs. the unlipidated 29-AA backbone; the lipidated form must be confirmed by MS. Non-lipidated survodutide would have dramatically shorter half-life and different pharmacokinetics. Confirm the correct lipidated MW explicitly in the COA.
Key Research Findings
- Dual GLP-1R + GCGR mechanism: GLP-1R ↓ energy intake (appetite suppression, gastric emptying inhibition, glucose-dependent insulin secretion); GCGR ↑ energy expenditure (BAT thermogenesis, lipolysis, hepatic fatty acid oxidation). Additive effects vs. GLP-1R monotherapy documented in Phase 2.
- ~8-fold GLP-1R selectivity over GCGR: Designed to ensure GLP-1R-mediated insulin secretion predominates over GCGR-mediated hepatic glucose output; prevents clinically significant hyperglycemia despite GCGR activation.
- Phase 2 obesity (Lancet Diabetes Endocrinol 2024, PMID: 38330987): ~15%+ body weight reduction at 4.8 mg once-weekly at 46 weeks; >50% of participants achieved ≥15% weight loss; dose-dependent across all tested doses.
- Phase 2 MASH (NEJM 2024, PMID: 38857022): Superior to placebo for MASH improvement; 64.5% fibrosis reduction in F2–F3 subgroup. First dual GCGR/GLP-1R compound to demonstrate significant antifibrotic activity in published MASH trial.
- Phase 3 SYNCHRONIZE program active: SYNCHRONIZE-1 (obesity without T2D); SYNCHRONIZE-2 (obesity + T2D). Not research-grade; NDA not filed as of April 2026.
- Distinct from semaglutide (GLP-1R only), tirzepatide (GLP-1R + GIPR), and cagrilintide (AMY1R/AMY3R): Three different pharmacological strategies for next-generation obesity pharmacology; survodutide is the glucagon receptor energy expenditure approach.
- C18 fatty diacid lipidation at Lys-24: Albumin binding → ~7-day half-life; same lipidation strategy as semaglutide. Adsorption to plastic surfaces at low concentrations is a research handling consideration.
- ~97% Premier margin at YPB: High clinical pipeline interest + growing research demand for non-GLP-1R-monoagonist metabolic compounds.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Survodutide Data Point |
|---|---|
| Search volume trend | New/rising rapidly; driven by Phase 2 publications (2024) and Phase 3 SYNCHRONIZE enrollment |
| Key Phase 2 publications | Lancet Diabetes Endocrinol 2024 (obesity, PMID: 38330987); NEJM 2024 (MASH, PMID: 38857022) |
| Unique mechanism | Only GLP-1R + GCGR dual agonist in YPB catalog; only compound combining appetite suppression with glucagon-driven energy expenditure and direct hepatic lipid oxidation |
| MASH research interest | Survodutide is one of the first compounds to demonstrate antifibrotic activity in MASH; GCGR-mediated hepatic steatosis reduction is a novel mechanism for liver biology research |
| Premier margin | ~97% at Premier tier (per YPB catalog data) |
| Research field context | MASH/MASLD (formerly NASH/NAFLD) is a rapidly growing research area with significant unmet clinical need; GLP-1R/GCGR dual agonism is an active area of investigation for liver-directed therapy |
How Can Researchers Offer Survodutide Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB Catalog (RUO) | Survodutide (BI 456906) | TBC Premier | TBC Core | TBC | ~97% at Premier tier |
Contact the YPB team for confirmed SKU number, configuration, Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering survodutide alongside cagrilintide create the most mechanistically differentiated next-generation metabolic research catalog available: GLP-1R + GCGR energy balance (survodutide) + AMY1R/AMY3R brainstem satiety (cagrilintide) = two Phase 3 compounds from distinct receptor systems addressing obesity research from different pharmacological angles. Together with AOD 9604 and MOTS-c, the metabolic research catalog covers four non-overlapping mechanisms for studying obesity-related biology. Download the full catalog for complete metabolic category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed and ClinicalTrials.gov searched for “survodutide,” “BI 456906,” “ZP2929,” “GCGR GLP-1R dual agonist obesity,” and “SYNCHRONIZE trial.” Search conducted through April 2026.
Key sources: le Roux et al. (2024) Lancet Diabetes Endocrinol (PMID: 38330987; Phase 2 obesity); Sanyal et al. (2024) NEJM (PMID: 38857022; Phase 2 MASH); ADA 2025 presentation (1974-LB molecular basis of survodutide dual agonism; cryo-EM structural data); Zimmermann et al. (2022) Mol Metab (BI 456906 preclinical pharmacology); SYNCHRONIZE-2 baseline characteristics (Wharton et al. 2025, Diabetes Obes Metab).
Limitations: YPB survodutide is research-grade RUO material, not a Boehringer Ingelheim compound preparation. Not research-grade; Phase 3 results pending. GI adverse events (nausea, vomiting) are common during dose titration, consistent with GLP-1R/GCGR class. GCGR-mediated hepatic glucose output is counterbalanced by GLP-1R-mediated insulin secretion in the designed compound, but the pharmacological balance may vary in research model systems. This article is for educational purposes only.
References
- le Roux, C. W., Steen, O., Lucas, K. J., Startseva, E., Unseld, A., & Hennige, A. M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol, 12(3), 162–173. PMID: 38330987
- Sanyal, A. J., Bedossa, P., Fraessdorf, M., et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med, 391(4), 311–319. PMID: 38857022
- Zimmermann, T., Thomas, L., Baader-Pagler, T., et al. (2022). BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab, 66, 101633.
- Wharton, S., Buse, J. B., Fraessdorf, M., et al. (2025). Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide for obesity in people with type 2 diabetes. Diabetes Obes Metab, 28(1).
- Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab, 27(4), 740–756. (GLP-1R pharmacology context.)
- Heppner, K. M., & Müller, T. D. (2017). Glucagon regulation of food intake and energy homeostasis. Curr Diab Rep, 17(11), 97. (GCGR obesity pharmacology context.)
- American Diabetes Association. (2025). 1974-LB: The molecular basis of survodutide (BI456906) glucagon/GLP-1 receptor dual agonism. ADA 85th Scientific Sessions. (Cryo-EM structural characterization.)
- Day, J. W., Ottaway, N., Patterson, J. T., et al. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol, 5(10), 749–757. (Foundational dual GCGR/GLP-1R agonism preclinical context.)
- Pocai, A., Carrington, P. E., Adams, J. R., et al. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258–2266.
Frequently Asked Questions
Survodutide (BI 456906; 29 AA; glucagon-derived backbone; C18 fatty diacid at Lys-24; ~7-day half-life; once-weekly SC) is a dual GLP-1R/GCGR agonist developed by Boehringer Ingelheim. In research models it activates two complementary metabolic pathways: GLP-1R (appetite suppression via hypothalamic arcuate/PVN; gastric emptying inhibition; glucose-dependent insulin secretion) + GCGR (energy expenditure increase: BAT thermogenesis, adipose lipolysis, hepatic fatty acid oxidation, glycogenolysis). Phase 2 obesity data: ~15%+ body weight reduction at 4.8 mg once-weekly at 46 weeks (Lancet Diabetes Endocrinol 2024, PMID: 38330987). Phase 2 MASH data: 64.5% fibrosis reduction in F2–F3, superior to placebo (NEJM 2024, PMID: 38857022). Phase 3 SYNCHRONIZE active. Not research-grade as of April 2026. Research Use Only (RUO). Updated April 2026.
All three are injectable once-weekly SC peptides with weight-reducing effects, but they activate different receptor combinations. Semaglutide is a GLP-1R monoagonist; it works exclusively through GLP-1R to suppress appetite and improve glycemia. Tirzepatide is a GLP-1R + GIPR dual agonist; it adds GIP receptor agonism to GLP-1R, which primarily enhances glucose-dependent insulin secretion and modulates adipocyte energy storage. Survodutide is a GLP-1R + GCGR dual agonist; it adds glucagon receptor agonism to GLP-1R, which primarily increases energy expenditure (thermogenesis, lipolysis, hepatic fatty acid oxidation) and provides direct hepatic steatosis reduction via GCGR-mediated fatty acid β-oxidation. The metabolic biology research question each compound addresses is different: semaglutide = pure GLP-1R pharmacology; tirzepatide = GLP-1R + incretin enhancement (GIP); survodutide = GLP-1R + counter-regulatory energy expenditure (glucagon). For liver/MASH research, survodutide’s GCGR component adds a direct hepatic mechanism not present in semaglutide or tirzepatide.
GLP-1R agonism primarily reduces energy intake: it suppresses appetite, slows gastric emptying, and improves glycemia. It has minimal direct effect on energy expenditure (basal metabolic rate). Survodutide adds GCGR agonism which directly increases energy expenditure through three mechanisms: (1) brown adipose tissue (BAT) thermogenesis activation (more calories burned at rest); (2) adipose tissue lipolysis (mobilizes stored fat as fuel); (3) hepatic fatty acid β-oxidation (burns fat in the liver rather than storing it as steatosis). Animal models showed survodutide produced significantly greater weight loss than equimolar doses of selective GLP-1R agonists, consistent with the additive mechanisms. In Phase 2 human trials, the ~15%+ weight reduction at the highest dose compares favorably with semaglutide 2.4 mg (~15%, STEP trials) while potentially providing the additional liver benefit. The Phase 3 SYNCHRONIZE data will establish the head-to-head difference more definitively.
This is the key pharmacological design challenge in GCGR/GLP-1R dual agonism and the question most thoroughly addressed in survodutide’s molecular design. Glucagon normally raises blood glucose by driving hepatic glycogenolysis and gluconeogenesis — and this would typically cause hyperglycemia if used alone. Survodutide resolves this through two mechanisms: (1) Concurrent GLP-1R agonism drives glucose-dependent insulin secretion from pancreatic β-cells. Unlike non-incretin insulin secretagogues, GLP-1R-stimulated insulin secretion is glucose-dependent: it amplifies insulin release when glucose is elevated but not at normal or low glucose, providing an automatic glycemic safety valve that counteracts GCGR-mediated hepatic glucose output without causing hypoglycemia. (2) Survodutide was designed with ~8-fold selectivity for GLP-1R over GCGR, ensuring GLP-1R-mediated effects predominate. In Phase 2 trials, survodutide did not produce significant hyperglycemia despite the GCGR component, validating the pharmacological design. In subjects with type 2 diabetes (SYNCHRONIZE-2), glycemic improvements were documented rather than worsening.
The Phase 2 MASH trial (Sanyal et al., NEJM 2024, PMID: 38857022) is significant for survodutide for two reasons. First, demonstrating superior MASH improvement vs. placebo with 64.5% fibrosis reduction in F2–F3 subgroups establishes survodutide as a potential treatment for the progressive form of metabolic-associated steatohepatitis, which has limited approved treatment options and is a major area of unmet clinical need. Second, the GCGR component is proposed as a key contributor to the liver-specific effects: GCGR activation in hepatocytes drives fatty acid β-oxidation (burning fat rather than storing it as steatosis), reduces de novo lipogenesis, and may directly reduce hepatic inflammation beyond the indirect effects of weight loss. This makes survodutide’s liver data mechanistically distinct from semaglutide’s MASH data, where the liver improvement is attributed primarily to weight loss rather than a direct hepatic receptor effect. For researchers studying MASH biology, survodutide’s GCGR component offers a pharmacological probe for the direct hepatic GCGR signaling axis in steatosis and fibrosis models.
Survodutide and cagrilintide are both injectable once-weekly metabolic research compounds with Phase 3 data, but they activate entirely different receptor systems. Survodutide activates GLP-1R (class B GPCR; Gs/cAMP; gut, brain, pancreas) and GCGR (class B GPCR; Gs/cAMP; liver, adipose, BAT). Cagrilintide activates AMY1R and AMY3R (heterodimeric CTR/RAMP complexes; Gq/11; primarily area postrema brainstem and hypothalamic arcuate nucleus). The mechanisms are completely non-overlapping: survodutide addresses energy balance through an appetite suppression + energy expenditure increase dual strategy; cagrilintide addresses appetite through a centrally acting brainstem satiety + gastric emptying + glucagon suppression strategy. Researchers studying incretin or glucagon receptor pharmacology use survodutide; researchers studying amylin receptor brainstem satiety circuits use cagrilintide. In clinical development, Novo Nordisk’s CagriSema combines cagrilintide with semaglutide (a GLP-1R monoagonist), suggesting that amylin receptor satiety and GLP-1R pathways are additive — complementary to the GLP-1R + GCGR approach of survodutide, not competing with it.
Yes. YourPeptideBrand.com provides white-label dropship for research-grade survodutide (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with dual GLP-1R/GCGR mechanism descriptions, Phase 2 clinical context (clearly framed as research context, not the compound product), and COA library links. With ~97% Premier margin and rapidly growing research interest driven by the Phase 2 NEJM/Lancet publications and Phase 3 SYNCHRONIZE enrollment, survodutide is among the highest-growth-potential metabolic research compounds in the catalog. Contact the YPB team for confirmed configuration, SKU, Premier and Core pricing, and use the profit calculator to model projected revenue.
Every survodutide batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at the correct MW for the 29-AA lipidated form (C18 fatty diacid at Lys-24 must be confirmed; non-lipidated form would have substantially lower MW and dramatically shorter half-life), endotoxin (<1 EU/mg), TAMC, and TYMC. Lipidated MW confirmation is the critical quality parameter: the C18 diacid modification is entirely responsible for the ~7-day half-life that enables once-weekly research protocols; a non-lipidated batch would behave pharmacokinetically as a short-acting compound. All lots are traceable through the batch-specific COA library.
Key Takeaways
Research Takeaways
- Dual GLP-1R + GCGR mechanism: GLP-1R ↓ energy intake (appetite suppression + gastric emptying + glucose-dependent insulin); GCGR ↑ energy expenditure (BAT thermogenesis, lipolysis, hepatic fatty acid oxidation). Complementary, not conflicting.
- Phase 2 obesity (Lancet DE 2024, PMID: 38330987): ~15%+ weight reduction at 4.8 mg once-weekly at 46 weeks; >50% achieved ≥15% weight loss; dose-dependent across all doses.
- Phase 2 MASH (NEJM 2024, PMID: 38857022): 64.5% fibrosis reduction in F2–F3; superior to placebo; GCGR-mediated hepatic fatty acid oxidation proposed as direct liver mechanism beyond weight loss.
- ~8-fold GLP-1R selectivity over GCGR: Designed to prevent hyperglycemia; GLP-1R glucose-dependent insulin secretion automatically counterbalances GCGR hepatic glucose output; validated in Phase 2 (no significant hyperglycemia).
- Phase 3 SYNCHRONIZE active; not research-grade (April 2026): Multiple Phase 3 trials ongoing; NDA not filed as of April 2026.
- Distinct from cagrilintide (AMY1R/AMY3R), semaglutide (GLP-1R only), tirzepatide (GLP-1R + GIPR): Three different pharmacological strategies for next-generation obesity research.
- C18 diacid lipidation at Lys-24: Albumin binding → ~7-day half-life; adsorption to plastics at low concentrations; lipidated MW must be confirmed in COA.
Business Takeaways
- ~97% Premier margin — highest-margin metabolic compound alongside cagrilintide.
- New/rising search volume — Phase 2 NEJM/Lancet publications driving rapid growth.
- Only GLP-1R + GCGR compound in YPB catalog — unique dual mechanism; MASH/liver biology angle adds a research dimension no other metabolic compound covers.
- Survodutide + Cagrilintide metabolic pair covers two leading Phase 3 non-GLP-1R-monoagonist metabolic research programs from one catalog.
Ready to add survodutide to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”survodutide”]